Canada: For Your Phase 3 Global Trial Expansion
Oncology continues to be the largest and fastest growing therapeutic area in the clinical trials market, and a market dominated…
Doubly Nimble: why you should open global P1 clinical trials in Canada on Day 1
With agility increasingly becoming the most important global driver of success, it’s worth noting that Canadian oncology research center Phase…
Troubleshooting Underperforming Sites – Best Practices
It’s no surprise that an underperforming site can cause significant delays in meeting important accrual targets, data timelines, or study…
Special Report: What’s in Store for Global Clinical Trials in 2022 and Beyond?
The Global Clinical Trials Market was valued at $44.3B USD in 2020, and by 2028 is expected to reach $69.3B…
Lessons Learned Moving Forward – Audit Readiness & Remote Close-Out Visits
The COVID-19 pandemic has required the clinical research industry to find new and innovative ways to monitor investigative sites. Although…
Lessons Learned Moving Forward – Site Support & Remote Close Out
Nearly every aspect of society, including the way scientists conduct the testing of medicines has been affected by the COVID-19…
Why Not Canada for Your Phase 3 Global Trial Expansion?
Pre-pandemic oncology was both the largest and fastest growing therapeutic area in the clinical trials market. A key market trend…
Diversity in Clinical Trial Participants: Canada Holds Promise
Participant diversity in clinical trials can be quite challenging to achieve. With COVID the concern about appropriate demographic representation is…
The Canadian Landscape for Childhood Cancer Research
Pediatric Hematology Oncology is a relatively recent area of study. Only in the past 50 years have substantial advances taken…
2020 a Year Like No Other: What it Takes to Keep Ahead of Rapid Change
This time last year none of us imagined we were about to go through a year like no other, and…